Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ICMT | O60725 | 4/20 | 0.37 |
| ▸ | PER2 | O15055 | 4/20 | 0.37 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 5/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927868 | 1.00 | HTR2C (0.38) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL23927866 | 1.00 | HTR2C (0.38) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL8959518 | 0.82 | PER2 (0.40) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL9228920 | 0.82 | HTR2C (0.56) | HTR2CHTR2A | |
| SCHEMBL8959520 | 0.82 | PER2 (0.40) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL23927894 | 0.82 | HTR3A (0.36) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL23927897 | 0.82 | HTR3A (0.36) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL29780354 | 0.82 | HTR3A (0.36) | HTR2CHTR2AICMTPER2CRY1 | |
| SCHEMBL23927892 | 0.81 | HTR6 (0.45) | HTR2CHTR6 | |
| SCHEMBL23927889 | 0.81 | HTR6 (0.45) | HTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR2C 3/4885HTR2A 5/4885ICMT 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.